NovoCure Quarterly Balance Sheet
NASDAQ: NVCRHealth CareMedical/Dental InstrumentsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
NovoCure financial position
As of Jun 30, 2026, NovoCure reported total assets of $795.2 million, down 36.2% from a year earlier against total liabilities of $457.1 million. Shareholders' equity stood at $338.1 million, or 42.5% of assets. The company held $93.7 million in cash and equivalents.
The current ratio (current assets divided by current liabilities) was 2.89, meaning short-term assets cover obligations due within a year.
Summary generated from market data by MetaCap's automated system. Methodology
NovoCure balance sheet (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 93.70M | 87.53M | 93.55M | 342.12M | 149.62M | 127.28M | 163.77M | 185.42M | 164.80M | 453.76M | 240.82M | 154.86M |
| Receivables | 99.13M | 93.27M | 89.44M | 85.23M | 89.92M | 84.51M | 74.23M | 67.06M | 64.70M | 65.09M | 61.22M | 65.13M |
| Inventory | 42.22M | 43.46M | 41.11M | 39.10M | 40.21M | 39.47M | 35.09M | 39.10M | 40.44M | 42.39M | 38.15M | 36.81M |
| Total Current Assets | 638.52M | 631.66M | 646.73M | 1.20B | 1.08B | 1.09B | 1.11B | 1.10B | 1.09B | 1.00B | 1.03B | 1.05B |
| Property, Plant & Equipment | 75.37M | 76.28M | 77.61M | 79.98M | 80.33M | 79.60M | 77.66M | 73.25M | 66.48M | 58.92M | 51.48M | 45.56M |
| Total Assets | 795.19M | 787.93M | 804.33M | 1.36B | 1.25B | 1.25B | 1.24B | 1.22B | 1.21B | 1.12B | 1.15B | 1.15B |
| Accounts Payable | 130.73M | 127.24M | 122.23M | 118.92M | 103.68M | 95.09M | 105.09M | 91.32M | 90.17M | 84.32M | 94.39M | 79.67M |
| Total Current Liabilities | 220.71M | 217.58M | 223.23M | 776.01M | 749.63M | 743.30M | 756.39M | 735.00M | 169.18M | 160.23M | 179.12M | 157.16M |
| Long-Term Debt | — | — | 195.05M | — | — | — | 97.30M | — | — | 569.65M | 568.82M | 567.99M |
| Total Liabilities | 457.10M | 457.21M | 463.86M | 1.02B | 896.43M | 886.85M | 880.61M | 861.21M | 850.42M | 762.07M | 783.63M | 752.65M |
| Shareholders' Equity | 338.09M | 330.72M | 340.47M | 341.33M | 349.44M | 361.96M | 360.18M | 360.78M | 361.75M | 359.36M | 362.50M | 393.70M |
| Retained Earnings | -1.38B | -1.36B | -1.29B | -1.27B | -1.23B | -1.19B | -1.15B | -1.09B | -1.06B | -1.02B | -985.50M | -938.42M |
| Total Debt | — | — | 195.05M | — | — | — | 97.30M | — | — | 569.65M | 568.82M | 567.99M |
| Net Cash (Debt) | 93.70M | 87.53M | -101.50M | 342.12M | 149.62M | 127.28M | 66.47M | 185.42M | 164.80M | -115.89M | -328.00M | -413.13M |
| Shares Outstanding | 116.44M | 115.82M | 112.49M | 111.98M | 111.80M | 111.48M | 108.52M | 108.10M | 108.01M | 107.60M | 107.08M | 106.75M |
This table shows 12 quarterly periods of NovoCure's balance sheet, from Q2 2026 back to Q3 2023, across 16 line items including cash & equivalents, receivables, inventory. Values in USD; B = billions, M = millions. Fiscal periods follow NVCR's reporting calendar. What is a balance sheet?